Netherlands Awards Roche Contract for Cervical Cancer Screening Program Using Cobas HPV Assay | GenomeWeb

NEW YORK (GenomeWeb) – Roche today announced that Dutch authorities have awarded it a five-year contract to implement the Cobas HPV test to replace traditional Pap smear testing as the first-line, primary screening test in the country's national cervical cancer screening program. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.